Soleno Therapeutics

About Soleno Therapeutics

Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative treatments for rare diseases. The company primarily focuses on patients suffering from Prader-Willi syndrome (PWS) and other rare endocrine disorders. Soleno's lead product candidate, DCCR (Diazoxide Choline Extended Release) tablets, is an oral medication designed for once-daily use. This product has received Orphan Drug Designation in both the United States and Europe, and it has been designated a Fast Track development program by the FDA, highlighting its potential to address significant unmet medical needs.

Soleno operates in the biopharmaceutical market, targeting a niche segment of rare diseases. The company's business model revolves around advancing its research and development pipeline to bring effective treatments to market. Revenue generation is anticipated through the commercialization of its lead product, DCCR, upon regulatory approval. The company serves a specialized client base, including patients, families, and healthcare providers dealing with rare endocrine disorders.

Soleno's commitment to making a positive impact on patients' lives is evident in its focus on advancing promising research and its dedication to diversity as an equal opportunity employer. The company is supported by a robust leadership team and board of directors with extensive experience in life sciences and investment management.